Double blind randomized controlled trial of efficacy of ormeloxifene for the treatment of fibroadenoma (The FIBROCENT study)

Abstract

AbstractBackgroundWe evaluated the effectiveness of Ormeloxifene (Centchroman) on regression of Fibroadenoma in a double‐blind randomized controlled trial.MethodsPatients with biopsy proven Fibroadenoma were enrolled between March 2023 and October 2023 and divided in two arms‐ Ormeloxifene group and Placebo group. Effectiveness of the treatment was evaluated using USG. No residual mass was defined as complete regression and more than 30% decrease in size was considered as partial regression.ResultsA total of 130 consecutive patients with Fibroadenoma were randomized to Ormeloxifene group (n = 65) and Placebo Group (n = 65). Complete regression was observed in 9% (6/65) patients in Ormeloxifene group and 10.8% (7/65) in Placebo Group at the end of 12 weeks (p = 0.49). Twenty one patients taking Ormeloxifene reported adverse events as compared to none in the other group.ConclusionIn our study Ormeloxifene was not found to be effective in treatment of fibroadenoma and had concerning side effects.